Prime Medicine, Inc.
PRME- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001894562
No open-market purchases or sales by Prime Medicine, Inc. insiders were filed in the last 90 days; 187 institutions reported holding it in 13F filings for Q2 2026, worth $393.5M in total; ARK Invest is the only superinvestor holding it.
Q3 2025 vs. Q2 2025
How the institutions holding Prime Medicine, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 121 | 167 | +46 |
| Shares | 58.7M | 92.3M | +33.7M (+57.4%) |
| Value | $145.0M | $511.5M | +$366.5M (+252.7%) |
New holders (53)
Institutions that held Prime Medicine, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (7)
Institutions that held Prime Medicine, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Jaffetilchin Investment Partners, LLC | 37,744 | $93.2K |
| SG Americas Securities, LLC | 27,919 | $69.0K |
| CIBC World Markets Inc. | 14,326 | $35.4K |
| R Squared Ltd | 12,519 | $30.9K |
| State Board of Administration of Florida Retirement System | 11,420 | $28.2K |
| Eqis Capital Management, Inc. | 10,432 | $25.8K |
| Fogel Capital Management, Inc. | 10,000 | $24.7K |